| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On CNBC's “Mad Money Lightning Round,” on Tuesday, Jim Cramer said Sempra (NYSE:SRE) is a buy.
Supporting his view, Wells Fargo analyst Shahriar Pourreza initiated coverage of Sempra on Tuesday with an Overweight rating and a price target of $115.
“You can own it, they've got to figure out something,” Cramer said when asked about Pfizer Inc. (NYSE:PFE). “That yield will protect you for a while though.”
Pfizer announced on Oct. 14 the initial results from a clinical trial called HER2CLIMB-05. This trial tested a new treatment for patients with a type of breast cancer (metastatic breast cancer (MBC)) that is positive for HER2, which means the cancer cells have a specific protein that helps them grow.
Dow Inc. (NYSE:DOW) can go higher, Cramer said. “I think you're ok in Dow, I would hold on to that.”
On the earnings front, Dow, on Oct. 23, reported a lower-than-expected third-quarter loss. The chemical company reported an adjusted loss of 19 cents per share, beating the Wall Street’s projected 29-cent loss, according to consensus estimates. Revenue fell 8% year over year (Y/Y) to $9.97 billion, missing the $10.23 billion estimate.
“I still can't believe it's around,” Cramer said when asked about Plug Power Inc. (NASDAQ:PLUG). “How much money can you lose over a certain period of time and still be allowed to be called a stock?”
The hydrogen fuel cell company saw its stock fall over 20% last week after announcing a warrant inducement agreement to raise $370 million. The deal, priced at $2.00 per share, sparked concerns about shareholder dilution, overshadowing several positive operational developments.
Price Action:
Read Next:
Image created using photos from Shutterstock.
